关键词：骨质疏松症；低骨密度；结构恶化；骨脆性增加；骨折风险增加
摘 要：Osteoporosis, or porous bones, is characterized by low bone density and structural deterioration of bone tissues, which lead to bone fragility and increase the risk of fractures. The disease develops when bone resorption occurs too quickly or when replacement happens too slowly. Gender, age, body size (low body weight), ethnicity, and family history can increase the risk of developing this disease. Medication use, calcium and vitamin intake, alcohol intake, and smoking are other major risk factors.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

06.1 Understanding Osteoporosis

06.2 Epidemiology and Demography

06.3 Risk Factors

06.4 Symptoms

06.5 Diagnosis

06.6 Treatment

07. Key Development in Osteoporosis Therapy

08. Market Landscape

08.1 Market Overview

08.1.1 Market Size and Forecast

08.2 Osteoporosis Drugs Market in US

08.2.1 Market Size and Forecast

08.3 Osteoporosis Drugs Market in Europe

08.3.1 Market Size and Forecast

08.4 Five Forces Analysis

09. Market Segmentation by Therapeutic Class

09.1 Global Osteoporosis Drugs Market by

Therapeutic Class 2014-2019

09.2 Antiresorptive Medications

09.3 Anabolic Medications

10. Market Segmentation by Line of Therapy

10.1 Global Osteoporosis Drugs Market by Line of

Therapy

11. Pipeline Assessment

11.1 Key Information about Pipeline Candidates

12. Geographical Segmentation

12.1 Global Osteoporosis Drugs Market by

Geographical Segmentation 2014-2019

12.2 Osteoporosis Drugs Market in Americas

12.2.1 Market Size and Forecast

12.3 Osteoporosis Drugs Market in EMEA

12.3.1 Market Size and Forecast

12.4 Osteoporosis Drugs Market in APAC

12.4.1 Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.1.3 Vendor Ranking 2014

20.1.4 Competitive Assessment of Major Drugs

20.1.5 Amgen

20.1.6 Eli Lilly

20.1.7 Merck

20.1.8 Novartis

20.2 Other Prominent Vendors

21. Key Vendor Analysis

21.1 Amgen

21.1.1 Key Facts

21.1.2 Business Overview

21.1.3 Business Segmentation by Revenue 2013

21.1.4 Product Portfolio by Revenue 2013

21.1.5 Business Segmentation by Revenue 2012 and 2013

21.1.6 Geographical Segmentation by Revenue 2013

21.1.7 Business Strategy

21.1.8 Recent Developments

21.1.9 SWOT Analysis

21.2 Eli Lilly

21.2.1 Key Facts

21.2.2 Business Overview

21.2.3 Business Segmentation by Revenue

21.2.4 Sales by Geography

21.2.5 Business Strategy

21.2.6 Key Information

21.2.7 SWOT Analysis

21.3 Merck & Co. Inc.

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Business Segmentation by Revenue 2013

21.3.4 Business Segmentation by Revenue 2012 and 2013

21.3.5 Sales by Geography

21.3.6 Business Strategy

21.3.7 Key Developments

21.3.8 SWOT Analysis

21.4 Novartis AG

21.4.1 Key Facts

21.4.2 Business Description

21.4.3 Business Segmentation

21.4.4 Revenue by Business Segmentation

21.4.5 Revenue Comparison 2012 and 2013

21.4.6 Sales by Geography

21.4.7 Business Strategy

21.4.8 Key Developments

21.4.9 SWOT Analysis

22. Other Reports in this Series